Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Elliot Newman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7932-2891; OpenAlex author ID A5030753298. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 4 papers · 2025: 4 papers · 2026: 1 paper

Papers 13

  1. Survival Disparities in Early-Onset Pancreatic Cancer (EOPC): The Role of Socioeconomic Status and Healthcare Access. Co-author DOI 10.1002/jso.70148↗
  2. Evaluating the Association of Area Deprivation Index (ADI) on Postoperative Outcomes in Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27996↗
  3. Impact of Environmental Quality on Pancreatic Cancer Outcomes Post Pancreatoduodenectomy: A Retrospective Cohort Study. Co-author DOI 10.1007/s12029-025-01254-4↗
  4. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. Co-author DOI 10.1093/oncolo/oyaf271↗
  5. Standard-Adherent Surgery and Guideline-Based Therapy in Pancreatic Cancer: A Multicenter Analysis. Co-author DOI 10.1245/s10434-025-17467-7↗
  6. Machine learning to predict completion of treatment for pancreatic cancer. Co-author DOI 10.1002/jso.27812↗
  7. Outcomes of minimally invasive vs. open pancreatoduodenectomies in pancreatic adenocarcinoma: analysis of ACS-NSQIP data. Co-author DOI 10.1007/s00423-024-03454-1↗
  8. Modified 5-Item Frailty Index (mFI-5) may predict postoperative outcomes after pancreatoduodenectomy for pancreatic Cancer. Co-author DOI 10.1007/s00423-024-03483-w↗
  9. Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S. Co-author DOI 10.1007/s12029-024-01119-2↗
  10. Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do? Co-author DOI 10.33696/signaling.2.037↗
  11. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Co-author DOI 10.1245/s10434-019-07685-1↗
  12. Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. Last author DOI 10.21037/jgo.2017.10.04↗
  13. Effect of intra-operative fluid volume on peri-operative outcomes after pancreaticoduodenectomy for pancreatic adenocarcinoma. Last author DOI 10.1002/jso.22048↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marcovalerio Melis · 10 shared papers, 2012–2026 · strength 2.02
  2. Abdullah Khalid · 8 shared papers, 2024–2026 · strength 1.91
  3. Danielle K. DePeralta · 7 shared papers, 2024–2026 · strength 1.70
  4. Sepideh Gholami · 7 shared papers, 2024–2026 · strength 1.70
  5. Matthew John Weiss · 7 shared papers, 2024–2025 · strength 1.59
  6. Daniel A. King · 6 shared papers, 2024–2025 · strength 1.33
  7. Shamsher Ali Pasha · 5 shared papers, 2024–2025 · strength 1.11
  8. Lyudmyla Demyan · 4 shared papers, 2024–2025 · strength 0.90
  9. Oliver J. Standring · 3 shared papers, 2024–2025 · strength 0.69
  10. Matthew J. Weiss · 1 shared paper, 2026 · strength 0.32
  11. Deirdre Jill Cohen · 2 shared papers, 2018–2025 · strength 0.31
  12. Lawrence Leichman · 1 shared paper, 2025 · strength 0.22
  13. Tanios Bekaii‐Saab · 1 shared paper, 2025 · strength 0.22
  14. Aaron James Scott · 1 shared paper, 2025 · strength 0.22
  15. Colin D. Weekes · 1 shared paper, 2025 · strength 0.22
  16. Wells A. Messersmith · 1 shared paper, 2025 · strength 0.22
  17. Alec J. Megibow · 1 shared paper, 2025 · strength 0.22
  18. Paul E. Oberstein · 1 shared paper, 2025 · strength 0.22
  19. Shreya Prasad Goyal · 1 shared paper, 2021 · strength 0.16
  20. Muhammad Wasif Saif · 1 shared paper, 2021 · strength 0.16
  21. Salvatore Amodeo · 1 shared paper, 2018 · strength 0.08
  22. Theresa M. Ryan · 1 shared paper, 2018 · strength 0.08
  23. Howard S. Höchster · 1 shared paper, 2018 · strength 0.08
  24. Eric Peter Tamm · 1 shared paper, 2019 · strength 0.07
  25. Robert A. Wolff · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.